Thyrocare Technologies Ltd's Board of Directors has in-principle approved the evaluation of a proposed demerger of its wholly-owned subsidiary Nueclear Healthcare Limited's radiology business undertaking. The strategic move, discussed at a board meeting on July 23, 2026, aims to transfer the radiology operations outside the group through a scheme of arrangement, slump sale, business transfer, or another appropriate structure. This restructuring is intended to streamline operations and optimize the group's portfolio.

The Proposed Restructuring is currently at an in-principle evaluation stage. Detailed terms will be placed before the Board of Directors of Nueclear Healthcare Limited at an appropriate time. Following this, necessary disclosures and filings will be made with the stock exchanges and other regulatory or statutory authorities as applicable.

Nueclear Healthcare Limited is engaged in advanced cancer diagnostics and nuclear medicine. The subsidiary operates PET-CT and CT imaging centres, provides nuclear medicine diagnostic services, and manufactures radiopharmaceuticals through its medical cyclotron facilities. These services support the early detection, diagnosis, staging, and monitoring of cancer and other complex diseases.

Thyrocare Technologies Ltd will ensure compliance with all applicable regulatory requirements, including under the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, at each stage of the Proposed Restructuring. This includes timely intimation to the stock exchanges.

The board meeting commenced at 2:45 P.M. and concluded at 03:35 P.M. on July 23, 2026.

Thyrocare Technologies has made the audio recording of its post-results earnings conference call publicly available, providing investors with direct access to management’s commentary on its latest financial performance. The call was held on July 23, 2026, at 6:00 PM IST, focusing on the company’s unaudited financial results for the quarter ended June 30, 2026. This disclosure ensures transparency and allows stakeholders to review the detailed discussion regarding operational metrics and financial outcomes for Q4FY27.

The release of the audio recording is in compliance with Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Thyrocare Technologies Limited submitted this disclosure to both the National Stock Exchange of India Limited and BSE Limited, ensuring adherence to mandatory reporting standards for listed entities in India.

Key Details of the Earnings Call

The conference call was conducted with analysts and investors to discuss the financial health and strategic direction of the company following the closure of the fiscal year. While the full transcript is yet to be shared, the audio recording provides immediate access to the verbal disclosures made by the company’s leadership team.

Availability and Next Steps

Investors and analysts can access the audio recording directly through the company’s investor relations portal at https://investor.thyrocare.com/financials/quarterly-financial-results/ . The company has indicated that a written transcript of the proceedings will be shared shortly after the initial release of the audio file. This sequential disclosure process allows for immediate auditory review while preparing a comprehensive textual record for archival and reference purposes.

Regulatory Compliance

The disclosure was authorized by Brijesh Kumar, Company Secretary and Compliance Officer of Thyrocare Technologies Limited. The submission underscores the company’s commitment to regulatory compliance under the SEBI Listing Regulations, ensuring that all material information regarding financial results is disseminated fairly and promptly to all market participants. The reference to the previous letter dated July 16, 2026, confirms the continuity of the disclosure timeline associated with the quarterly results announcement.